Robert Bissonnette
About
Robert Bissonnette is a scholar working on Dermatology, Immunology and Immunology and Allergy.
According to data from OpenAlex, Robert Bissonnette has authored 304 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 215 papers in Dermatology, 123 papers in Immunology and 93 papers in Immunology and Allergy. Recurrent topics in Robert Bissonnette's work include Dermatology and Skin Diseases (181 papers), Psoriasis: Treatment and Pathogenesis (100 papers) and Allergic Rhinitis and Sensitization (68 papers). Robert Bissonnette is often cited by papers focused on Dermatology and Skin Diseases (181 papers), Psoriasis: Treatment and Pathogenesis (100 papers) and Allergic Rhinitis and Sensitization (68 papers). Robert Bissonnette collaborates with scholars based in Canada, United States and Germany. Robert Bissonnette's co-authors include Kim Papp, Emma Guttman‐Yassky, Charles Lynde, Catherine Maari, Chantal Bolduc, Yves Poulin, James G. Krueger, Simon Nigen, Melinda Gooderham and Lyn Guenther and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.
In The Last Decade
Robert Bissonnette
286 papers receiving 11.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Bissonnette Canada | 61 | 7.1k | 4.6k | 2.8k | 2.2k | 1.9k | 304 | 11.4k | ||
| Lone Skov Denmark | 58 | 5.5k 0.8× | 6.6k 1.4× | 1.7k 0.6× | 1.9k 0.8× | 1.7k 0.9× | 389 | 12.9k | ||
| Andreas Wollenberg Germany | 54 | 8.5k 1.2× | 2.5k 0.5× | 6.1k 2.2× | 1.7k 0.8× | 2.8k 1.5× | 320 | 12.0k | ||
| Diamant Thaçi Germany | 56 | 7.7k 1.1× | 8.3k 1.8× | 2.7k 1.0× | 3.2k 1.5× | 2.5k 1.3× | 375 | 13.5k | ||
| Werner Aberer Austria | 56 | 4.4k 0.6× | 1.8k 0.4× | 4.2k 1.5× | 1.9k 0.9× | 1.2k 0.6× | 290 | 10.5k | ||
| Wolf‐Henning Boehncke Germany | 55 | 4.4k 0.6× | 8.7k 1.9× | 917 0.3× | 2.7k 1.2× | 1.4k 0.7× | 356 | 13.2k | ||
| Ulrich Mrowietz Germany | 60 | 5.9k 0.8× | 7.5k 1.6× | 719 0.3× | 1.4k 0.6× | 1.4k 0.8× | 331 | 12.7k | ||
| Lawrence F. Eichenfield United States | 57 | 8.9k 1.2× | 1.5k 0.3× | 5.4k 1.9× | 1.2k 0.6× | 2.1k 1.1× | 448 | 12.2k | ||
| David M. Pariser United States | 45 | 4.0k 0.6× | 2.5k 0.5× | 1.0k 0.4× | 747 0.3× | 882 0.5× | 220 | 7.3k | ||
| Mariana Castells United States | 59 | 2.0k 0.3× | 3.6k 0.8× | 3.8k 1.3× | 2.7k 1.2× | 2.2k 1.2× | 228 | 10.3k | ||
| John Koo United States | 55 | 6.8k 1.0× | 8.0k 1.7× | 1.0k 0.4× | 1.7k 0.8× | 1.1k 0.6× | 339 | 12.5k |
Countries citing papers authored by Robert Bissonnette
Since
Specialization
Citations
This map shows the geographic impact of Robert Bissonnette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Bissonnette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Bissonnette more than expected).
Fields of papers citing papers by Robert Bissonnette
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert Bissonnette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Bissonnette. The network helps show where Robert Bissonnette may publish in the future.
Co-authorship network of co-authors of Robert Bissonnette
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Bissonnette. A scholar is included among the top collaborators of Robert Bissonnette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Bissonnette. Robert Bissonnette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gold, Linda Stein, Robert Bissonnette, Seth Forman, et al.. (2025). A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. American Journal of Clinical Dermatology. 26(2). 275–289.
2.
Ferris, Laura K., Jerry Bagel, Yu-Huei Huang, et al.. (2024). FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 92(3). 495–502.
3.
Silverberg, Jonathan I., Lawrence F. Eichenfield, Adelaide A. Hebert, et al.. (2024). Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. Journal of the American Academy of Dermatology. 91(3). 457–465.
4.
Lebwohl, Mark, Michael Bukhalo, Linda Stein Gold, et al.. (2024). A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. Journal of the American Academy of Dermatology. 91(6). 1150–1157.
5.
Bissonnette, Robert, Richard B. Warren, Andreas Pinter, et al.. (2024). Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. The Lancet. 404(10451). 461–473.
6.
Simpson, Eric L., Jonathan I. Silverberg, Robert Bissonnette, et al.. (2024). 671 - Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis. British Journal of Dermatology. 191(Supplement_2).
7.
Beck, Lisa A., Robert Bissonnette, Mette Deleuran, et al.. (2024). Dupilumab in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology. 160(8). 805–805.
8.
Potvin, Diane, et al.. (2024). Adaptive designs in dermatology clinical trials: Current status and future perspectives. Journal of the European Academy of Dermatology and Venereology. 38(9). 1694–1703.
9.
Sofen, Howard, Robert Bissonnette, Gil Yosipovitch, et al.. (2023). Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 57. 101826–101826.
10.
Bissonnette, Robert, Andreas Pinter, Laura K. Ferris, et al.. (2023). 78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1. Journal of Investigative Dermatology. 143(11). S345–S345.
11.
Mehta, Heena, Carolyn Jack, Catherine Maari, et al.. (2023). Oral prednisone regulates human skin T cells in delayed‐type hypersensitivity reaction elicited by diphencyprone. Allergy. 78(8). 2255–2265.
12.
Burden, A. David, Robert Bissonnette, Mark Lebwohl, et al.. (2023). Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA ) and generalized pustular psoriasis area and severity index (GPPASI ). Journal of the European Academy of Dermatology and Venereology. 37(7). 1327–1335.
13.
Bissonnette, Robert, et al.. (2023). Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials. Journal of Clinical Medicine. 12(11). 3805–3805.
14.
Renert‐Yuval, Yael, Jacob P. Thyssen, Robert Bissonnette, et al.. (2021). Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council. Journal of Allergy and Clinical Immunology. 147(4). 1174–1190.e1.
15.
Silverberg, Jonathan I., Emma Guttman‐Yassky, Tove Agner, et al.. (2020). Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council. Dermatitis. 32(5). 319–326.
16.
Abuabara, Katrina, Jonathan I. Silverberg, Eric L. Simpson, et al.. (2020). International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open. 10(11). e039928–e039928.
17.
Reich, Kristian, Phoebe Rich, Catherine Maari, et al.. (2019). Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study. British Journal of Dermatology. 181(1). 88–95.
18.
Guttman‐Yassky, Emma, Benjamin Ungar, Kunal Malik, et al.. (2017). Molecular signatures order the potency of topically applied anti-inflammatory drugs in atopic dermatitis patients. Journal of Allergy and Clinical Immunology. 140(4).
19.
Bissonnette, Robert, Kim Papp, Yves Poulin, et al.. (2016). Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. British Journal of Dermatology. 175(5). 902–911.
20.
Braathen, Lasse R., Rolf‐Markus Szeimies, Nicole Basset‐Séguin, et al.. (2006). Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. Journal of the American Academy of Dermatology. 56(1). 125–143.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lone Skov Breakdown of academic impact, for papers by Andreas Wollenberg Breakdown of academic impact, for papers by Diamant Thaçi Breakdown of academic impact, for papers by Werner Aberer Breakdown of academic impact, for papers by Wolf‐Henning Boehncke Breakdown of academic impact, for papers by Ulrich Mrowietz Breakdown of academic impact, for papers by Lawrence F. Eichenfield Breakdown of academic impact, for papers by David M. Pariser Breakdown of academic impact, for papers by Mariana Castells Breakdown of academic impact, for papers by John Koo